SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a ...
BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with the latter’s Keytruda (pembrolizumab) in a global Phase I/II trial for ...
WUXI, China, June 21, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for ...
SHANGHAI, July 8, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2 ...
BioCity, a pioneering life science incubator and business collective, today announced an investment in INCUS Performance, further solidifying their position as a keen investor in promising ventures.
BioCity Biopharma (BioCity), a clinical-stage biopharmaceutical company, announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in ...
BioCity, a pioneering life science incubator and business collective, has announced a new strategic partnership with Oxford AHSN. Working in partnership, the Oxford Academic Health Science Network and ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. When BioCity Nottingham, the UK’s biggest biomedical business incubator, opened just over five years ago, ...
BioCity, a pioneering life science incubator and business collective, has announced a new strategic partnership with Oxford AHSN. Working in partnership, the Oxford Academic Health Science Network and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results